Future investigations should focus on larger patient cohorts, longitudinal follow-up, and the integration of ACSL4 with other clinical parameters to determine its potential as a standalone or combined marker for early diagnosis and prognosis assessment in PCa. Here, ACSL4 is linked to posterior cortical atrophy.